Balchem Corp (FRA:BL9B)

Q2 2026 Balchem Corp Earnings Call Transcript

Jul 31, 2026 / 03:00 PM GMT

Release Date Price: €138

Transcript 10-Q8-K

Key Points

Positve

Record quarterly consolidated sales of $284 million, up 11.2% year-over-year, driven by broad-based growth across all three segments.
Record quarterly adjusted EBITDA of $78 million, up 12.6%, with adjusted EBITDA margin of 27.4%.
Strong growth in Animal Nutrition & Health, with sales up 15% and earnings from operations up 48.7%, driven by adoption of rumen-protected technologies and recovery in European monogastric business.
Specialty Products delivered record quarterly sales of $41 million, up 8.9%, and record earnings from operations of $13 million, up 14.4%.
Completed refinancing of revolving credit facility, increasing borrowing capacity from $550 million to $650 million and extending maturity to 2031, enhancing financial flexibility.
Repurchased approximately $29 million of common stock during the quarter, reflecting commitment to shareholder returns.
Achieved 28th consecutive quarter of year-over-year growth in adjusted EBITDA, demonstrating consistent execution and resilience.
Human Nutrition & Health segment delivered record sales of $177 million, up 10%, driven by strong demand for nutrients and food ingredients.
Gross margin expanded to 36.5% of sales, up 10 basis points, despite higher input costs.
Net debt remains low at $89 million with leverage ratio of 0.3, providing ample capacity for growth investments.

Negative

Higher manufacturing input costs, including those related to the conflict in the Middle East, partially offset margin gains.
Effective tax rate increased to 22.8% from 21.9% in the prior year, primarily due to lower tax benefits from stock-based compensation.
Operating expenses increased to $44 million from $42 million, driven by higher compensation-related costs.
Cash flows from operations were relatively low at $4.7 million, though free cash flow was $36 million.
The company faces ongoing uncertainty from geopolitical conflicts, which could impact input costs and supply chains.
Interest expense, while lower, remains a cost, and the new credit facility has a variable rate that could rise with future Fed rate hikes.
The European monogastric business, while improving, is still recovering from past anti-dumping issues, and the full benefit may take time to materialize.
The company's growth is partly dependent on consumer trends in 'better-for-you' products, which could shift with changing consumer preferences.
The pending results of the MD Anderson study on choline and cognition are uncertain, and if unfavorable, could impact future marketing claims.
Despite strong performance, the company faces competitive pressures in the nutrient market, requiring ongoing investment in science and marketing to maintain differentiation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCPC.OQ - Balchem Corp
Q2 2026 Balchem Corp Earnings Call
Jul 31, 2026 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, everyone.

Thank you for joining us and welcome to the Belgium second quarter 2026, earnings call.

After today's prepared remarks, we will host a question-and-answer session.

If you would like to ask a question, please press 1.

To withdraw your question, press 1 again.

I would now like to hand the conference over to Martin Benkston, Malcolm Seat.

CEO, please go ahead.

Morning, everyone.

Thank you for joining our conference call this morning to discuss the results of Balkan Corporation for the quarter ending June 30th, 2026.

My name's Martin Banksson, Chief Financial Officer and hosting this call with me is Ted Harris, our Chairman, President and CEO.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.